The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind ...

The biotech will stop developing two drugs and lay off nearly three-quarters of its staff after its lead therapy wasn’t as potent in early testing as the company expected.

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.